Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784746 | 0.84 | ALK (0.44) | HTR2CPDE4BEGFRALKCHEK1 | |
| SCHEMBL1784640 | 0.83 | QDPR (0.63) | PDE4BEGFRALKCHEK1QDPR | |
| SCHEMBL16991978 | 0.80 | HTR2C (0.48) | HTR2CPDE4BALKTLR9TLR7 | |
| SCHEMBL26655031 | 0.79 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTTGFBR1ACVR1 | |
| SCHEMBL18764013 | 0.79 | MEN1 (0.58) | PDE4BEGFRQDPRPDE4APDE4C | |
| SCHEMBL18310123 | 0.78 | HTR2C (0.49) | HTR2CPDE4BTLR9TLR7CHEK1 | |
| SCHEMBL2473309 | 0.78 | PDE4B (0.64) | HTR2CPDE4BTLR9TLR7QDPR | |
| SCHEMBL18764021 | 0.77 | EGFR (0.49) | PDE4BEGFRTLR9TLR7CHEK1 | |
| SCHEMBL10407705 | 0.77 | QDPR (0.66) | HTR2CPDE4BQDPRALDH1A1 | |
| SCHEMBL13645913 | 0.77 | HTR2C (0.48) | HTR2CPDE4BTLR9TLR7QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
| EP-2212326-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009024824-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | HTR2C 3500/4885PDE4B 1979/4885EGFR 1/4885 |
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | HTR2C 4708/4885PDE4B 4299/4885EGFR 2420/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | HTR2C 3500/4885PDE4B 1979/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.